BeiGene has become the latest Chinese biotech to list on the Hong Kong stock exchange, raising $903m, near the top of its target range. The company – which has just started pivotal trials for its lead …
( read original story …)
The HongKong News
BeiGene has become the latest Chinese biotech to list on the Hong Kong stock exchange, raising $903m, near the top of its target range. The company – which has just started pivotal trials for its lead …
( read original story …)